Brief: Reata Pharmaceuticals Announces Approval Of Prior Approval Supplement For Skyclarys® (Omaveloxolone) And Commercial Availability Of Skyclarys For Patients With Friedreich's Ataxia
28/06/2023 24:30
June 27 (Reuters) - Reata Pharmaceuticals Inc RETA.O :
* REATA PHARMACEUTICALS ANNOUNCES APPROVAL OF PRIOR APPROVAL
SUPPLEMENT FOR SKYCLARYS® (OMAVELOXOLONE) AND COMMERCIAL
AVAILABILITY OF SKYCLARYS FOR PATIENTS WITH FRIEDREICH’S ATAXIA
* REATA PHARMACEUTICALS INC - WITH APPROVAL OF PAS,
SKYCLARYS IS
NOW AVAILABLE TO PATIENTS WITH FRIEDREICH'S ATAXIA IN UNITED
STATES
Source text for Eikon: ID:nBwbcYY9Qa
Further company coverage: RETA.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Reata Pharmaceuticals
See all newsReata Pharmaceuticals Inc reports results for the quarter ended in June - Earnings Summary
Reata Pharmaceuticals Inc expected to post a loss of $2.88 a share - Earnings Preview
Brief: Biogen Inc Says If Deal Terminated Under Certain Conditions, Reata Will Be Required To Pay Biogen Termination Fee Equal To $264 Mln
U.S. STOCKS ON THE MOVE-US regional banks, Enphase, Centene
Biogen’s $7 bln deal goes smaller and safer